Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

Background: Tigecycline and cefoperazone/sulbactam can cause coagulation disorders; tigecycline may also lead to hypofibrinogenemia, raising safety concerns. This study aimed to investigate whether tigecycline plus cefoperazone/sulbactam increases the risk of bleeding compared with other tigecycline...

Full description

Bibliographic Details
Main Authors: Lei Zhang, Xinfeng Cai, Fangchen Peng, Shuangshuang Tian, Xinjing Wu, Yun Li, Jinlin Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Pharmacology
Subjects:
tigecycline
cefoperazone/sulbactam
carbapenems
β-lactam antibiotics
coagulation disorders
hypofibrinogenaemia
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1182644/full

Similar Items

Similar Items